June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Evaluation of the Safety and Efficacy of OTX-TP, an intracanalicular travoprost insert, for the treatment of patients with open-angle glaucoma or ocular hypertension: A Phase 3 Study
Author Affiliations & Notes
  • Srilatha Vantipalli
    Medical Affairs, Ocular Therapeutix, Waltham, Massachusetts, United States
  • Kenneth N Sall
    Sall Eye Research Medical Center, California, United States
  • Emil Stein
    Nevada Eye Care, Nevada, United States
  • Howard Schenker
    Rochester Ophthalmological Group, New York, United States
  • Jay Mulaney
    Central Florida Eye Associates, Florida, United States
  • Robert Smyth-Medina
    North Valley Eye Medical Group, California, United States
  • Douglas Day
    Coastal Research Associates, Georgia, United States
  • Robert Benza
    Apex Eye, Ohio, United States
  • El-Roy Dixon
    Dixon Eye Care, Georgia, United States
  • Nicole Rissman
    Medical Affairs, Ocular Therapeutix, Waltham, Massachusetts, United States
  • Jamie Lynne Metzinger
    Medical Affairs, Ocular Therapeutix, Waltham, Massachusetts, United States
  • Michael H Goldstein
    Medical Affairs, Ocular Therapeutix, Waltham, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Srilatha Vantipalli, Ocular Therapeutix (E); Kenneth Sall, Ocular Therapeutix (F); Emil Stein, Ocular Therapeutix (F); Howard Schenker, Ocular Therapeutix (F); Jay Mulaney, Ocular Therapeutix (F); Robert Smyth-Medina, Ocular Therapeutix (F); Douglas Day, Ocular Therapeutix (F); Robert Benza, Ocular Therapeutix (F); El-Roy Dixon, Ocular Therapeutix (F); Nicole Rissman, Ocular Therapeutix (E); Jamie Metzinger, Ocular Therapeutix (E); Michael Goldstein, Ocular Therapeutix (E)
  • Footnotes
    Support  This trial was supported in full by Ocular Therapeutix.
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3488. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Srilatha Vantipalli, Kenneth N Sall, Emil Stein, Howard Schenker, Jay Mulaney, Robert Smyth-Medina, Douglas Day, Robert Benza, El-Roy Dixon, Nicole Rissman, Jamie Lynne Metzinger, Michael H Goldstein; Evaluation of the Safety and Efficacy of OTX-TP, an intracanalicular travoprost insert, for the treatment of patients with open-angle glaucoma or ocular hypertension: A Phase 3 Study. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3488.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : OTX-TP (travoprost ophthalmic insert) is a resorbable hydrogel-based insert delivering travoprost in a sustained-release fashion to the ocular surface over a 90-day period. Here we evaluate the safety and IOP-lowering efficacy of OTX-TP when placed in the canaliculus of the eyelid in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). This Phase 3 study was designed to assess a clinically meaningful response to treatment.

Methods : This was a prospective, multicenter Phase 3 trial. Patients diagnosed with OAG or OH were randomized (3:2) to receive in both eyes either OTX-TP or placebo vehicle insert (PV). Subjects completed follow-up visits at Weeks 2, 4, 6, 8, 10, 12 and 20. Primary endpoint was mean intraocular pressure (IOP) at 8AM, 10AM and 4PM at the 2, 6, and 12 Week visits. Safety evaluations included adverse event (AE) collection and exam findings, including slit lamp, dilated fundus, visual acuity exams, grading of ocular hyperemia and subjective ocular comfort assessment.

Results : 554 subjects with OAG or OH were enrolled at 50+ sites. OTX-TP treated subjects had a greater reduction in IOP from baseline relative to placebo insert at all 9 time points, and these differences were statistically significant (P<0.05) for eight of the nine time points. Reductions from baseline for OTX-TP treated subjects in this trial ranged from 3.27-5.72 mmHg across the 9 time points with higher levels of IOP reduction seen at the earlier time points in this trial. OTX-TP was generally well-tolerated and no ocular serious adverse events were observed. The most common ocular adverse events seen in the study eye were dacryocanaliculitis (approximately 7% in OTX-TP vs. 3% in placebo) and lacrimal structure disorder (approximately 6% in OTX-TP vs. 4% in placebo).

Conclusions : OTX-TP exhibits fair IOP lowering with a single insert, with a greater magnitude of effect early in the drug’s lifecycle. Adverse events were transient, mild and resolved over time.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×